Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

XW Labs of Wuhan In-licenses Mitochondria Candidates from the University of Pittsburgh

publication date: Mar 6, 2017
XW Labs, a three-year old novel drug R&D company based in Wuhan, China, in-licensed exclusive rights to a class of innovative compounds based on mitochondria targeted bis-nitroxide technology for CNS and oncology indications. The technology was developed at the University of Pittsburgh in the laboratory of Professor Peter Wipf. In animal tests, the compounds showed efficacy in models of Huntington's Disease and traumatic brain injury. XW, which hopes to start clinical trials of the candidates by the end of 2017, did not disclose financial details. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital